Table 3.
Linear mixed effect models showing EQ-5D utility and VAS trajectories
| Variable | EQ-5D utility | VAS | ||
|---|---|---|---|---|
| Estimates (SE) | P value | Estimates (SE) | P value | |
| Clinical stage | < 0.001 | < 0.001 | ||
| SCD | Reference | Reference | ||
| MCI | − 0.015 (0.004)a | − 1.695 (0.274)a | ||
| Mild | − 0.077 (0.015)a | − 4.401 (0.676)a | ||
| Moderate | − 0.053 (0.021)a | − 4.999 (0.8)a | ||
| Severe | 0.043 (0.158) | − 15.386 (3.142)a | ||
| Time (year) | − 0.007 (0.001) | < 0.001 | − 0.518 (0.062) | < 0.001 |
| Clinical stage × time interaction | < 0.05 | |||
| SCD × time | Reference | |||
| MCI × time | 0 (0.002) | |||
| Mild × time | 0.005 (0.005) | |||
| Moderate × time | − 0.015 (0.006)a | |||
| Severe × time | − 0.09 (0.04)a | |||
Models adjusted for baseline age, sex, education, and BMI. We did not include clinical stage and time interaction term in the VAS model since there was no interaction effect and no model improvement
VAS Visual analogue scale, SCD Subjective cognitive decline, MCI Mild cognitive impairment
aStatistically significant